Gait differences between COPD and healthy controls: systematic review and meta-analysis
- PMID: 38657998
- PMCID: PMC11040389
- DOI: 10.1183/16000617.0253-2023
Gait differences between COPD and healthy controls: systematic review and meta-analysis
Abstract
Background: Despite the importance of gait as a determinant of falls, disability and mortality in older people, understanding of gait impairment in COPD is limited. This study aimed to identify differences in gait characteristics during supervised walking tests between people with COPD and healthy controls.
Methods: We searched 11 electronic databases, supplemented by Google Scholar searches and manual collation of references, in November 2019 and updated the search in July 2021. Record screening and information extraction were performed independently by one reviewer and checked for accuracy by a second. Meta-analyses were performed in studies not considered at a high risk of bias.
Results: Searches yielded 21 085 unique records, of which 25 were included in the systematic review (including 1015 people with COPD and 2229 healthy controls). Gait speed was assessed in 17 studies (usual speed: 12; fast speed: three; both speeds: two), step length in nine, step duration in seven, cadence in six, and step width in five. Five studies were considered at a high risk of bias. Low-quality evidence indicated that people with COPD walk more slowly than healthy controls at their usual speed (mean difference (MD) -19 cm·s-1, 95% CI -28 to -11 cm·s-1) and at a fast speed (MD -30 cm·s-1, 95% CI -47 to -13 cm·s-1). Alterations in other gait characteristics were not statistically significant.
Conclusion: Low-quality evidence shows that people with COPD walk more slowly than healthy controls, which could contribute to an increased falls risk. The evidence for alterations in spatial and temporal components of gait was inconclusive. Gait impairment appears to be an important but understudied area in COPD.
Copyright ©The authors 2024.
Conflict of interest statement
Conflict of interest: A. Polhemus is a paid employee of Merck & Co, Inc. and IQVIA AG. S.C. Buttery reports educational speaker fees for Pulmonx. J. Garcia-Aymerich reports speaker honoraria from Chiesi and a grant from AstraZeneca paid to her institution for a COVID-19-related project and is also a paid advisory board member for AstraZeneca. All other authors report no conflicts of interest.
Figures
 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                References
- 
    - Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2023. Available from: http://goldcopd.org/
 
- 
    - Núñez-Cortés R, Padilla-Acevedo P, Vergara-Peña F, et al. . Clinical assessment of balance and functional impairments in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. ERJ Open Res 2022; 8: 00164-2022. doi:10.1183/23120541.00164-2022 - DOI - PMC - PubMed
 
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Medical
 
        